Here is why that matters
Basic pharmacokinetic parameters including absorption, distribution, metabolism, and excretion characteristics in human subjects would inform rational dosing strategies and identify potential sources of pharmacokinetic variability affecting individual response
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al
Each spray delivers 100 mcg of BPC-157 and 100 mcg of TB-500, for a combined 200 mcg per spray
It is worth noting that we used TAT peptide as the control peptide in this study rather than the second N-terminus fragment of DAT (A 16 P 26 ) from our previous study [23]
Day 30 onward: Transition to BPC-157 Delay Pro (slow-release for continued repair and maintenance)